I'm not trying to trash or invalidate that study or its authors.
I'm saying that from a scientific standpoint, the evidence for a reduction in opioid use in that study is not going to convince the CMS to approve RecoveryRx for reimbursement under the NOPAIN Act.
For the reasons I stated.
I guess we'll have to wait for 2025 to see if I'm right.